• 1
    Howarth PH. The cellular basis for allergic rhinitis. Eur J Allergy Clin Immunol 1995;50:610.
  • 2
    Belda J, Parameswaran K, Keith PK, Hargreave FE. Repeatability and validity of cell and fluid-phase measurements in nasal fluid: a comparison of two methods of nasal lavage. Clin Exp Allergy 2001;31:11111115.
  • 3
    Knowles MR, Carson JL, Collier AM, Gatzy JT, Boucher RC. Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo. Am Rev Respir Dis 1981;124:484490.
  • 4
    Boucher RC, Bromberg PA, Gatzy JT. Airway transepithelial electric potential in vivo: species and regional differences. J Appl Physiol 1980;48:169176.
  • 5
    Suzumura E, Takeuchi K. Antigen reduces nasal transepithelial electric potential differences and alters ion transport in allergic rhinitis in vivo. Acta Otolaryngol 1992;112:552558.
  • 6
    Wang D, Duyck F, Smitz J, Clement P. Efficacy and onset of action of fluticasone propionate aqueous nasal spray on nasal symptoms, eosinophil count, and mediator release after nasal allergen challenge in patients with seasonal allergic rhinitis. Allergy 1998;53:375382.
  • 7
    Proud D, Reynolds CJ, Lichtenstein LM, Kagey-Sobotka A, Togias A. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. Clin Exp Allergy 1998;28:868875.
  • 8
    Kavuru M, Melamed J, Gross G, Laforce C, House K, Prillaman B et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000;105:11081116.
  • 9
    Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:14051411.
  • 10
    Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996;154:308317.
  • 11
    Johnson M. Interactions between corticosteroids and β2-agonists in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004;1:200206.
  • 12
    Gagliardo R, Merendino A, Pompeo F, Siena L, Bellia V, Testi R et al. IKKβ phosphorylation is modulated by the combination of glucocorticosteroids and long acting β2-agonists in human bronchial epithelial cells. Am J Respir Crit Care Med 2003;167:A653.
  • 13
    Seeto LJ, Johnson M, Hendel N, Lim S. Effect of dexamethasone and salmeterol on human alveolar macrophage cytokine production in patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2002;165:A597.
  • 14
    Eickelberg O, Roth M, Lörx R, Bruce V, Rüdiger J, Johnson M et al. Ligand-independent activation of the glucocorticoid receptor by the β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999;274:10051010.
  • 15
    Roth M, Johnson PR, Rudiger JJ, King GG, Ge Q, Burgess JK et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002 26;360:12931299.
  • 16
    Li X, Ward C, Thien F, Bish R, Bamford T, Bao X et al. An anti-inflammatory effect of salmeterol, a long-acting β2-agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999;160:14931499.
  • 17
    Paulsen DF. Respiratory system. In: PaulsenDF, editor. Basic histology, 2nd edn. Englewood Cliffs: Prentice Hall, 1993:24654.
  • 18
    Myo S, Zhu X, Myou S, Meliton AY, Liu J, Boetticher E et al. Additive blockade of beta 2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate. Eur Respir J 2004;23:511517.
  • 19
    Sartori C, Allemann Y, Duplain H, Lepori M, Egli M, Lipp E et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 2002;346:16311636.
  • 20
    Coraux C, Kileztky C, Polette M, Hinnrasky J, Zahm JM, Devillier P et al. Airway epithelial integrity is protected by a long-acting beta2-adrenergic receptor agonist. Am J Respir Cell Mol Biol 2004;30:605612.